Sales 2024 by Business Segment

Sales 2024 by Geography

Historical Breakdown of Revenue by Business Segments

Gross Profit: Breakdown by Business Segment

Breakdown by Business Segment (CNY)
Fiscal Period: December 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

Life Sciences Tools and Services

          

Chemical Business

- 1.41TCr 2.88TCr 2.92TCr 2.91TCr

Gross Profit

- 556.52Cr 1.15TCr 1.3TCr 1.35TCr

Test Business

- 452.51Cr 571.87Cr 653.97Cr 567.07Cr

Gross Profit

- 143.45Cr 199.5Cr 244.57Cr 185.61Cr

Biology Business

- 198.51Cr 247.51Cr 255.26Cr 254.39Cr

Gross Profit

- 77Cr 96Cr 103Cr 96Cr

High-end therapy CTDMO business (Wu Xi ATU)

- 102.64Cr 130.8Cr 130.96Cr -

Gross Profit

- -2.08Cr -8.74Cr -13Cr -

Clinical Research and Other CRO Services

116.89Cr - - - -

Gross Profit

17Cr - - - -

US District Laboratory Services

151.66Cr - - - -

Gross Profit

33Cr - - - -

Laboratory Services in China

854.58Cr - - - -

Gross Profit

359.44Cr - - - -

Unallocated Other

2.21Cr 2.75Cr 3.36Cr 4.1Cr 65Cr

Gross Profit

1.15Cr 1.31Cr 1.57Cr 2.1Cr 20Cr

Gross Profit

- - - - -21Cr

Pharmaceutical Contract Research Organization

          

Domestic New Drug Research and Development Service Unit (Wu Xi DDSU)

528.21Cr 125.1Cr 97Cr 73Cr -

Gross Profit

217.7Cr 55Cr 25Cr 26Cr -

Geographical Revenue Distribution History

Geographical breakdown of sales (CNY)
Fiscal Period: December 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

Overseas

- - - 3.3TCr 3.09TCr

Total Assets

352.37Cr - - - -

China

414.53Cr 580.2Cr 752.6Cr 733.05Cr 704.76Cr

Total Assets

- - - - -

Asia

68Cr - - - -

Total Assets

1.27TCr - - - -

Rest of World

20Cr 123.4Cr 151.2Cr - -

Asia (Except China)

- - - - -

Europe

265.08Cr 371.9Cr 443.2Cr - -

United States

886.19Cr 1.21TCr 2.59TCr - -